Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Venetoclax shows 79% VGPR or CR in relapsed/refractory AL amyloidosis; high t(11;14)(>10%) pts achieved ≥ VGPR in 91% vs 33% in low t(11;14); cardiac responses in 59% of evaluable patients; 1-yr OS and EFS of 96.6% and 82.6%.”
Title: Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis
Authors: Xin-yi Xiong, Ai Guan, Yi Xu, Cheng-yang Xu, Kai-ni Shen, Jian Li
You can read the Full Article in Annals of Hematology.
You can find more posts featuring Robert Orlowski on OncoDaily.
